Ascentage Pharma Group International (ASPHF) Stock Price Prediction

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 567 full-time employees. The company went IPO on 2019-10-28. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The firm mainly conducts its business in the domestic market.